Catabasis Pharmaceuticals Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Catabasis Pharmaceuticals Inc
TickerATXS
CIK #0001454789
CUSIP04635X102
SectorLife Sciences - Pharmaceutical Preparations
AddressOne Kendall Square Bldg 1400E, Suite B14202, Cambridge, MA 02139
Source [EDGAR]
CIK Filing 2011 - 2024
[0001454789] 10-K
[0001454789] 10-Q
[0001454789] 3
[0001454789] 4
[0001454789] 5
[0001454789] 8-K
[0001454789] D
[0001454789] SC 13D
[0001454789] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
FMR LLC Astria Therapeutics Inc [2023-01-10] 0.0
Deep Track Capital LP Astria Therapeutics Inc [2022-12-22] 7.32
Altium Capital Management LP Astria Therapeutics Inc [2022-12-21] 5.2
Vivo Opportunity LLC Astria Therapeutics Inc [2022-09-08] 7.1
Cormorant Asset Management LP Astria Therapeutics Inc [2022-09-02] 5.38
Rosalind Advisors Inc Astria Therapeutics Inc [2022-01-07] 5.0
Fairmount Funds Management LLC Catabasis Pharmaceuticals Inc [2021-06-17] 5.3
Viridian LLC Catabasis Pharmaceuticals Inc [2021-06-17] 0.99
RA Capital Management LP Catabasis Pharmaceuticals Inc [2021-06-15] 7.5
Perceptive Advisors LLC Catabasis Pharmaceuticals Inc [2021-02-08] 10.5
BlackRock Inc Catabasis Pharmaceuticals Inc [2021-02-02] 5.8
Altium Capital Management LP Catabasis Pharmaceuticals Inc [2020-02-10] 7.4
Armistice Capital LLC Catabasis Pharmaceuticals Inc [2019-02-19] 4.99
Federated Investors Inc /PA/ Catabasis Pharmaceuticals Inc [2018-07-10] 14.7
Armistice Capital LLC Catabasis Pharmaceuticals Inc [2018-07-02] 4.99
Stonepine Capital Management LLC Catabasis Pharmaceuticals Inc [2018-06-28] 6.5
Empery Asset Management LP Catabasis Pharmaceuticals Inc [2018-06-25] 7.04
Corriente Advisors LLC Catabasis Pharmaceuticals Inc [2018-02-23] 7.3
Astrazeneca PLC Catabasis Pharmaceuticals Inc [2017-02-10] 10.7
Flynn James E Catabasis Pharmaceuticals Inc [2016-09-30] 4.21
Clarus Lifesciences II LP Catabasis Pharmaceuticals Inc [2016-02-19] 17.99
Advanced Technology Ventures VII LP Catabasis Pharmaceuticals Inc [2016-02-16] 7.4
FMR LLC Catabasis Pharmaceuticals Inc [2015-07-10] 0.0
SVLSF V LLC Catabasis Pharmaceuticals Inc [2015-07-08] 19.64
Camber Capital Management LLC Catabasis Pharmaceuticals Inc [2015-07-06] 6.38
Form 3/4/5 Filer 2011 - 2024
Astria Therapeutics, Inc.
Lapointe Anthony Gregg
Bate Kenneth
Beck Joanne T.
Clauser Noah
Morabito Christopher
Callori Fred
Cole Hugh M
Violin Jonathan
Milne Jill C.
Matthews Andrea
Komjathy Andrew
Harshbarger Benjamin
Kishbauch Michael D
Perceptive Xontogeny Venture Fund, LP
Perceptive Life Sciences Master Fund Ltd
Edelman Joseph
Perceptive Advisors LLC
Nichols Andrew John
Xontogeny, LLC
Adelman Burt A
Donovan Joanne M.
Cunnane Deirdre A.
Ross Michael Jay
George Jean
Hibben Edward K.
Modi Rick
Galakatos Nicholas
Sanderson Ian C.
Clarus Ventures II GP, L.P.
Clarus Ventures II, LLC
Clarus Lifesciences II, L.P.
Jirousek Michael
SVLSF V LLC
SV Life Sciences Fund V LP
SV Life Sciences Fund V Strategic Partners, L.P.
SV Life Sciences Fund V (GP), LP
MedImmune Ventures, Inc.
Laufer Ron
ATV Associates VIII, L.L.C.
Advanced Technology Ventures VIII LP
Form 13F Holdings
Firm Period DFND Voting Shares
FMR LLC [2023-03-31] DFND 3,217,978.0 3,217,978.0
Perceptive Advisors LLC [2023-03-31] SOLE 2,189,462.0 2,189,462.0
Fairmount Funds Management LLC [2023-03-31] SOLE 1,901,397.0 1,901,397.0
Deep Track Capital LP [2023-03-31] SOLE 1,816,531.0 1,816,531.0
Vivo Capital LLC [2023-03-31] SOLE 1,681,199.0 1,681,199.0
Driehaus Capital Management LLC [2023-03-31] SOLE 1,328,285.0 1,432,674.0
Altium Capital Management LP [2023-03-31] SOLE 1,347,088.0 1,347,088.0
Vanguard Group Inc [2023-03-31] SOLE 0.0 1,303,389.0
Logos Global Management LP [2023-03-31] SOLE 1,044,960.0 1,044,960.0
Cormorant Asset Management LP [2023-03-31] DFND 1,000,000.0 1,000,000.0
Ikarian Capital LLC [2023-03-31] SOLE 869,390.0 869,390.0
Affinity Asset Advisors LLC [2023-03-31] SOLE 529,369.0 529,369.0
Balyasny Asset Management LP [2023-03-31] SOLE 485,939.0 485,939.0
Ghost Tree Capital LLC [2023-03-31] SOLE 450,000.0 450,000.0
Sphera Funds Management Ltd [2023-03-31] DFND 421,018.0 421,018.0
Opaleye Management Inc [2023-03-31] SOLE 302,000.0 302,000.0
Millennium Management LLC [2023-03-31] SOLE 294,092.0 294,092.0
BlackRock Inc. [2023-03-31] SOLE 283,691.0 288,369.0
EAM Investors LLC [2023-03-31] SOLE 133,731.0 286,455.0
TRI Locum Partners LP [2023-03-31] SOLE 275,011.0 275,011.0
Susquehanna International Group LLP [2023-03-31] DFND 219,312.0 237,112.0
Geode Capital Management LLC [2023-03-31] DFND 233,836.0 233,836.0
Weiss Multi-Strategy Advisers LLC [2023-03-31] SOLE 206,388.0 206,388.0
Two Sigma Advisers LP [2023-03-31] SOLE 153,700.0 173,734.0
Polar Asset Management Partners Inc [2023-03-31] SOLE 154,200.0 154,200.0
Two Sigma Investments LP [2023-03-31] SOLE 141,020.0 141,020.0
Boothbay Fund Management LLC [2023-03-31] OTR 0.0 140,623.0
Jane Street Group LLC [2023-03-31] DFND 101,835.0 101,835.0
Saturn V Capital Management LLC [2023-03-31] SOLE 101,339.0 101,339.0
SilverArc Capital Management LLC [2023-03-31] SOLE 93,823.0 93,823.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com